CGRP antibodies were supposed to be the breakthrough. A targeted, monthly injection designed specifically for migraine - not repurposed from epilepsy or depression, but built from the ground up around migraine biology. Aimovig was the first, followed by Ajovy and Emgality.
For some people, they're transformative. For others - roughly half of patients in clinical trials - they don't meaningfully help. And for a smaller group, they worked for a while and then stopped.
If you're in that second or third group, you're not out of options. You're learning that CGRP isn't where your migraine system is under the most pressure - and that's valuable information.
Why this matters
CGRP antibodies provide the most sustained CGRP suppression available - 24/7 for a full month. If that level of CGRP blockade doesn't resolve your migraines, CGRP is almost certainly not your dominant driver. That narrows the search significantly.
How CGRP Antibodies Work (and How They Differ)
All three CGRP antibodies are monoclonal antibodies - large, engineered proteins injected monthly (or quarterly for Ajovy) that provide continuous CGRP suppression. But they work through two different approaches:
Receptor Blocker
Aimovig (erenumab)
Blocks the CGRP receptor itself, preventing CGRP from binding to it. Like putting a lock on a door - CGRP is still circulating, but it can't activate its target receptor.
Molecule Blockers
Ajovy (fremanezumab) & Emgality (galcanezumab)
Bind to the CGRP molecule itself, neutralizing it before it can reach any receptor. Like intercepting a messenger before they deliver the message.
This distinction matters for one practical reason: some patients who don't respond to the receptor blocker (Aimovig) do respond to a molecule blocker (Ajovy or Emgality), and vice versa. The mechanisms overlap but aren't identical. If one CGRP antibody fails, switching to the other type may be worth discussing before concluding the entire class doesn't work for you.
Why CGRP Antibodies Don't Work for Everyone
1. CGRP isn't your dominant driver
CGRP is involved in most migraines, but "involved" doesn't mean "dominant." If your migraines are primarily driven by histamine pathways, autonomic dysfunction, hormonal instability, or vascular underfill, blocking CGRP removes a minor player while the main drivers continue unchecked.
The clinical trials showed about 50% of chronic migraine patients achieved a meaningful reduction (50%+ fewer migraine days). That means for roughly half of patients, even sustained, continuous CGRP blockade wasn't enough - because CGRP wasn't the main story.
2. The migraine has centralized
CGRP antibodies are large molecules that don't easily cross the blood-brain barrier. They primarily work on peripheral CGRP signaling - in the trigeminal ganglion and meningeal blood vessels. In chronic migraine that has become centrally sensitized - where the brainstem and cortex have become independently reactive - peripheral CGRP blockade may not reach the pain processing centers that are now driving the attacks.
This may explain why CGRP antibodies tend to work better for episodic migraine than for long-standing chronic migraine with significant central sensitization.
3. Side effects create new problems
CGRP has functions beyond migraine. It helps regulate gut motility, blood vessel tone, and wound healing. Blocking it can produce:
- Constipation (especially with Aimovig) - sometimes severe enough to require intervention
- Muscle cramps and spasms - CGRP helps regulate vascular tone in muscle tissue
- Hypertension - CGRP is a vasodilator, so blocking it can raise blood pressure in some people
- Worsening Raynaud's symptoms - reduced vasodilation in extremities
In some cases, these side effects create enough systemic stress or autonomic disruption to partially offset the migraine benefit.
4. The pattern shifted
If a CGRP antibody worked initially and then lost effectiveness, your migraine pattern likely changed. Perimenopause, new medications, increased histamine sensitivity, worsened sleep, or new stressors can shift the dominant driver away from CGRP. The drug is still blocking CGRP just as effectively - but CGRP is no longer the main issue.
CGRP Antibodies vs Gepants: What Failure of One Tells You About the Other
If Aimovig (or Ajovy/Emgality) didn't work, you might wonder whether Nurtec or Ubrelvy (gepants) would be different. They target the same pathway but work differently:
CGRP antibodies provide constant, sustained blockade for 4 weeks. They're large molecules that work peripherally.
Gepants (Nurtec, Ubrelvy) are small molecules that provide shorter, intermittent blockade. They cross the blood-brain barrier more readily, potentially reaching central CGRP pathways.
Because of these differences, some patients who fail CGRP antibodies still respond to gepants (and vice versa). If you failed Aimovig but haven't tried Nurtec, it may still be worth discussing. However, if you've tried both a CGRP antibody and a gepant with no meaningful response, CGRP blockade as a strategy has been thoroughly tested - the driver is almost certainly elsewhere.
The more CGRP approaches you've tried without success, the stronger the signal: your migraines are not primarily CGRP-driven. That's not a failure - it's a diagnosis by exclusion that points the investigation toward histamine, vascular, hormonal, or autonomic pathways.
This Pattern May Fit You If
- • You've completed 3+ months of a CGRP antibody with minimal improvement
- • Aimovig helped initially but gradually lost effectiveness
- • Nurtec also didn't work (suggesting CGRP isn't your driver)
- • Your migraines come with congestion, flushing, or food-related patterns (suggesting histamine)
- • Migraines are clearly tied to hormonal timing, posture, or hydration
- • You developed significant constipation or muscle cramps on Aimovig
- • Multiple medication classes have failed and you've been labeled "treatment-resistant"
What to Discuss With Your Clinician
- • Whether switching between receptor blocker (Aimovig) and molecule blocker (Ajovy/Emgality) is worth trying before abandoning the class
- • Whether trying a gepant (Nurtec, Ubrelvy) could reach central CGRP pathways the antibodies missed
- • Whether investigating histamine, hormonal, vascular, or autonomic pathways could identify the actual driver
- • Whether the pattern of what has and hasn't worked narrows down the likely migraine mechanism
- • Whether combining a CGRP approach with treatment of other layers (sleep, sodium, hormonal stability) could improve the overall outcome
The Part Most People Miss
CGRP antibodies are the most targeted migraine treatment ever developed. When they don't work, it's not a failure of modern medicine - it's the clearest possible signal that your migraines live somewhere else in the system.
Each medication failure narrows the search. Triptans failed? Serotonin pathways aren't the answer. Topamax failed? Neural excitability isn't the primary driver. CGRP antibodies failed? CGRP isn't running the show. Botox failed? Peripheral nerve signaling isn't the main input. What's left? Histamine, vascular dynamics, hormones, autonomic regulation. The pattern of failures is itself a diagnostic tool.
This guide is for education and pattern-recognition only. It is not medical advice and is not a plan to start, stop, or change any medication, supplement, or test. Always discuss treatment decisions with a licensed clinician who knows your history.
Clinical and Review Articles
- Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. New England Journal of Medicine. 2017;377(22):2123-2132.
- Silberstein SD et al. Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. 2017;377(22):2113-2122.
- Stauffer VL et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurology. 2018;75(9):1080-1088.
- Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(S2):47-55.
Already have test results?
If you've accumulated years of normal tests but still have migraines, those records may contain patterns that haven't been examined together.
Related reading
This is educational content, not medical advice. Always consult a qualified clinician.